Diranersen

DRUG2 trials

Sponsors

Biogen

Conditions

Alzheimer's Disease DementiaHealthy VolunteerMild Cognitive Impairment Due to Alzheimer's Disease

Phase 1

A Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled Diranersen (BIIB080) Co-administered With Diranersen in Healthy Adults

CompletedNCT06454721

BiogenHealthy Volunteer

Start: 2025-01-30End: 2026-03-05Updated: 2026-07-10

Phase 2

A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruitingNCT05399888

BiogenAlzheimer's Disease Dementia, Mild Cognitive Impairment Due to Alzheimer's Disease

Start: 2022-08-24End: 2028-06-06Updated: 2026-06-30

Related Papers

Biomarker development for the tau therapeutic landscape

Alzheimer s & Dementia2025-12-01

Baseline characteristics from CELIA: A Phase 2 study to evaluate BIIB080 in participants with Early Alzheimer’s Disease

Alzheimer s & Dementia2025-12-01

Design of a Phase 2, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer’s Disease Dementia

Alzheimer s & Dementia2023-12-013 citations

Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial

Nature Medicine2023-04-24281 citations